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Abstract
The recent rapid acceleration of basic science is reshaping both our clinical research system and our
health care delivery system. The pace and growing volume of medical discoveries are yielding
exciting new opportunities, yet we continue to face old challenges to maintain research progress and
effectively translate research into practice. The National Institutes of Health and individual
government programs are increasingly emphasizing research agendas involving evidence
development, comparative effectiveness research among heterogeneous populations, translational
research, and accelerating the translation of research into evidence-based practice, as well as building
successful research networks to support these efforts. For over 25 years, the National Cancer
Institute's Community Clinical Oncology Program has successfully extended research into the
community and facilitated the translation of research into evidence-based practice. By describing its
keys to success, this article provides practical guidance to cancer-focused provider-based research
networks as well as those in other disciplines.
Clinical research and medicine have entered a time of great promise but also are faced with
new challenges. The rapid acceleration of basic science, including advances in genomics and
proteomics, are elucidating mechanisms of disease, yielding new methods to identify and
potentially treat abnormalities, and effectively are transforming acute diseases into chronic
ones. These advances signify substantial progress in our national research endeavor; however,
they simultaneously are reshaping not only the entire clinical research system, but also our
health care delivery system and the practice of clinical medicine. The pace and volume of
medical discoveries, and evolving clinical practice and corresponding policy, require the
development of new evidence in comparative effectiveness and outcomes, which have recently
seen tremendous investment increases through the American Recovery and Reinvestment Act
of 2009 and other substantial efforts 1-2. As we proceed through this transformation and face
new research and clinical practice demands, the question of how best to improve the translation
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of clinical research into clinical practice remains unanswered, and the substantial discovery-
delivery gap remains.
The National Institutes of Health (NIH) established the NIH Roadmap Initiative to address
these challenges and other needs in the scientific community 3. Through the Roadmap, as one
means of restructuring its clinical research enterprise, the NIH is exploring practice-based
research networks (PBRNs), to pursue the twin goals of accelerating science and facilitating
the translation of research into practice 4-6.
In terms of accelerating the science, PBRNs provide great promise in allowing access both a
greater number and a more heterogenous sample of prospective research participants. Both of
these elements are increasingly important to accelerating the pace of research progress, for
several reasons 4-5. First, intervention effectiveness is increasingly shown to hinge on specific
genotypes expressed in limited subsets of the population. This drives a need for research
population heterogeneity to assure inclusion of individuals expressing each of the relevant
genotypes. Second, this fuels the need for more clinical trials to examine different agents or
approaches that may be effective in treating these multiple population subgroups. Opening
more trials testing more agents necessitates more people to enroll on those trials to allow their
timely completion. Together with the long-held estimate that less than one percent of
Americans seeking health care do so at academic medical centers (heretofore the locus of nearly
all clinical trials) 7-8, filling these research needs mandates mechanisms such as PBRNs to
extend into the community and access a larger more heterogenous sample of prospective
research participants.
PBRNs can also facilitate the translation of research into practice by playing a central role in
a critical two-way flow of information 9-10. First, PBRNs connect academic investigators to
community practitioners who contribute “upstream” information to researchers regarding
study design and implementation considerations, including insight into the clinical issues and
tacit practice-based knowledge that exists in community-based practice settings. Second,
PBRNs can facilitate “downstream” dissemination and implementation of research results into
community-based clinical practice by promoting a sense of trust and ownership among
community-providers who were first-hand participants in the whole process, enhancing
providers’ acceptance of research results, and strengthening their commitment to acting on
research findings. This level of participation also often encourages practice organizational
changes that facilitate the research, and allows access to more, or earlier, information compared
with others who did not participate in the research. In this way, PBRNs contribute both
evidence-based practice and practice-based evidence, and help close the discovery-delivery
gap 11-12.
Despite PBRNs’ promise and substantial federal commitment to develop and support them in
a wide range of disease areas13-22, PBRNs face significant challenges with regard to
implementation and sustainability 23-28. Major challenges include (1) developing and
maintaining an infrastructure of clinicians and qualified staff, (2) maintaining adequate and
consistent funding for research, (3) developing collaborations with local physicians who
manage PBRN functions, and (4) instituting systems of accountability and efficiency 23, 28, all
of which are greatly facilitated by (5) establishing a cultural context that values research and
scientifically based practice 29. Recognizing these challenges is important; however, little
practical guidance exists in the literature regarding principles for addressing them in
establishing and operating effective PBRNs.
The National Cancer Institute (NCI)'s Community Clinical Oncology Program (CCOP) is a
cancer-focused PBRN that, since its establishment in 1983, has grown to contribute one third
of the NCI's clinical treatment trial enrollment and the overwhelming majority of its prevention
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and control trial enrollment (See Figure 1). Moreover, CCOP has been integral to not only core
accrual for NCI trials, but also the development of major trials such as the Breast Cancer
Prevention Trial (BCPT)30, the Study of Tamoxifen and Raloxifene (STAR) 31, and the
Selenium and Vitamin E Cancer Prevention Trial (SELECT) 32, which was designed by a
CCOP Research Base. In addition to providing 31% of BCPT's 13,388 participants, 33% of
STAR's 19,747 participants, and 29% of SELECT's 35,534 participants (allowing SELECT to
be completed well ahead of schedule), it is widely held that without the CCOP enhanced
infrastructure, these studies – most notably SELECT – could not have been started let alone
completed 33. Its current performance and critical centrality to such research is the result of
nearly 30 years’ direct experience, continuous self-evaluation, adaptation, and learning from
other NCI PBRNs and quality enhancement efforts, including the Cooperative Group Outreach
Program (CGOP) and the Community Hospital Oncology Program (CHOP) 34-35. To provide
practical guidance for other new and developing PBRNs, we discuss the organizational
characteristics and strategies that have contributed to its successfully addressing the challenges
of implementation and sustainability, and meeting the needs of clinical research and the
translation of research into evidence-based practice. We draw from three decades of evaluation
of the CCOP, CGOP, and CHOP programs 24-27, 34-43, and expand upon prior other recent
work 28 by discussing the current and evolving practical needs facing practice-based research.
Overview: The NCI Community Clinical Oncology Program
The NCI has established a national clinical trials infrastructure through the Cooperative
Groups, which are bodies of researchers, cancer centers, and community physicians who work
together to conduct trials. The CCOP is a PBRN and a component of NCI's clinical trials
program, through which community physicians participate as full research members in NCI's
clinical trials44 (see Table 1). The CCOP network funds community hospitals and physicians
to participate in NCI-funded clinical trials that are designed by NCI cancer centers and clinical
cooperative groups (collectively called “CCOP Research Bases”), commonly in conjunction
with the CCOP. The community-based networks of hospitals and physicians (“CCOP
organizations” or “local CCOPs”) and Research Bases are funded through peer-reviewed grants
based upon their productivity in developing, conducting, and accruing to clinical trials.
CCOP has a track record of translating findings from NCI-sponsored clinical trials to
community practice (see Table 2). It is the academic investigators within the Research Bases
who primarily drive the science, but the CCOP physicians participate in the development of
the trials and contribute substantial numbers of patients to the trials, and then translate that
science into practice by modifying their subsequent practice patterns based upon the results of
those trials. In this way, the CCOP program has facilitated the translation of several research-
based clinical innovations into practice. For example, Epidermal Growth Factor Receptor
(EGFR) inhibitors have demonstrated efficacy in patients with metastatic colorectal cancer that
have failed chemotherapy45. The CCOP network brought a large heterogeneous population of
patients to the trials, facilitating the identification of Kras, a protein in the EGFR pathway, as
a predictor of prospective treatment effectiveness 46. As a result of this study's findings,
practicing oncologists and patients considering cetuximab now can prospectively ascertain the
probability of treatment effectiveness and thus avoid unnecessary treatment risks, side-effects,
and their associated substantial costs. In addition to participating in the study (in terms of
offering the trial to his eligible patients), a CCOP investigator was a co-author in the ASCO
Guidance for screening patients 47, thus exemplifying the two-way communication between
research and practice in the CCOP network.
Similar to this, the CCOP network facilitated the completion of studies in the development of
OncoType DX, a genotype scoring system that evaluates patients’ risk of cancer recurrence.
Specimens and data from previous trials were used to develop and validate OncoType DX48
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and an ongoing NCI trial (PACCT 1) 49 will evaluate the need for chemotherapy in hormone
responsive patients with OncoType DX scores that are difficult to interpret. For physicians and
patients considering treatment, the findings of this study will better inform their balancing of
the risk of recurrence with other considerations, and whether the prospective chemotherapy
treatment benefits will justify the risks 50. These two examples build upon the enormous success
of several foundational adjuvant breast cancer trials, a few of which are presented in Table 2,
and demonstrate the centrality of the CCOP program in the evolving cancer research and
clinical care environment.
Keys to CCOP Success and Overcoming Challenges
In today's evolving research environment, at least four major challenges must be addressed by
PBRNs in order to continue medical progress that benefits patients, providers, and society (see
call-out box). Through a combination of experience, deliberation, and serendipity, the CCOP
has put into place structures, policies, and practices that address these challenges and have
contributed to its strong performance 28, 34-35.
Key Principle 1: Building an Infrastructure
Community-based physicians in a PBRN maintain the critical flow of patients into clinical
research studies and collaborate with academically based researchers to test new ideas in the
practice setting. In building a research infrastructure, physician interest is essential, but often
not sufficient. Community-based physicians face demanding schedules and heavy workloads.
A well-trained research staff, particularly research nurses, is critical to the successful
integration of clinical research into community oncologists’ practice 27, 42.
Research nurses help facilitate and integrate clinical research into physicians’ daily activities
and ensure that research-related activities offer minimal disruption to clinical practice and care.
Research nurses screen charts and flag them for patients eligible for trials, help physicians
communicate with patients about clinical research opportunities, and provide assistance with
other trial related activities. Physicians and nurses in CCOP trials form a critical mass of health
care providers who are comfortable with implementing and delivering the new treatment and
care strategies that arise from these trials 42.
In order to maintain high quality research, mechanisms for ongoing training and education for
all staff need to be in place. The CCOP research bases provide training and educational
opportunities twice a year for all affiliated academic and community-based physicians and
research staff. At a local level, CCOP organizations also provide affiliated physicians, research
nurses, and staff members with education and training sessions at which nationally known
speakers present the latest clinical and research developments. Training includes information
about protocol design for specific studies, as well as trial-related skills such as procedures for
enrolling participants, collecting and submitting trial data, and reporting adverse events 27.
Education and training activities vary across CCOP organizations depending on how they
choose to staff their operations 27, 42. Education includes continuing medical education
sessions for scientific discussions specific to the ongoing clinical trials. Several research bases
also offer mentoring programs for newer investigators and certification exams for the Society
of Clinical Research Associates. Training by the Research Bases and at the local CCOPs
provides an unprecedented opportunity to educate clinicians who might not otherwise be
exposed to clinical research, and such exposure also encourages uptake of new treatment
modalities.
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Key Principle 2: Funding to empower local physicians
Maintaining adequate and consistent funding for research is a persistent challenge in a research
enterprise. PBRNs must direct funds to community-based physicians who deliver care and
provide accrual for clinical trials. Although academic centers play a large role in a clinical trials
program, the CCOP program uses peer-reviewed cooperative agreements to award grant
funding directly to local networks of physicians and hospitals, rather than passing the money
through academic medical centers or intermediaries, thus contributing a great degree of local
flexibility to ensure the money is used to meet each site's specific needs. Providing grants
directly to the sites allows the local organizations to plan for multiple years of funding (for
stability), permits sites to plan and allocate staff, office infrastructure, and other resources
according to the research needs, and brings recognition of NIH funding to a community site.
At the same time as the cooperative agreements allow each CCOP flexibility, they also permit
substantial NCI management and oversight and provide a framework for regular performance
monitoring and financial reporting.
The stability and flexibility conveyed through direct funding is augmented by the CCOP
organizations affiliating with multiple research bases for a broad menu of trials that matches
the research interests of the organization and the population it serves. CCOP productivity is
measured by enrollment of patients to those trials in conjunction with data quality, and typically
CCOP will have over one hundred open trials. Budgetary flexibility allows each CCOP
organization to manage its staff, time, and other resources to best support the trials it has
selected to open, ensuring its ability to meet its accrual goals and otherwise be successful. As
an example of how the funding structure empowers decision-making by local communities,
the physicians and community served by the Upstate Carolina CCOP (South Carolina)
expressed strong interest in the NCI-sponsored prostate cancer clinical trial, the Selenium and
Vitamin E Cancer Prevention Trial (SELECT) 51. Accordingly, they re-allocated a large
proportion of their resources and staffing to support enrolling patients in this trial, resulting in
remarkably high accrual.
Each CCOP organization's funding is based upon accrual to all trials it has open, rather than
any one specific trial, and these accrual targets are set annually based on the availability of
trials and historical trends in the CCOP organization's patient accrual. Figure 2 illustrates the
funding of the CCOP program and average per-CCOP funding, and underscores the importance
of ensuring a relatively consistent, predictable level of funding from one year to the next to
enable CCOP organizations to maintain staffing and operations as trials open and close. Despite
significant ebbs and flows in levels of federal funding for clinical research and myriad changes
in the financing, structure, and delivery of health care 24, the cooperative agreement mechanism
helps ensure the viability of this system.
Key Principle 3: Collaboration strengthens research and practice
PBRNs help bridge the gap between academic research and community practice through
clinical research that addresses an identified need and will produce usable results. For a two-
way communication system between academic research and community practice to be
effective, clinicians must understand the importance of the research, and the research must be
responsive to the needs of the clinicians.
The CCOP structure provides many opportunities for interaction between clinicians and
academic researchers. CCOP research bases hold regular conferences during which
academically based researchers and CCOP-affiliated physicians and research staff meet in
scientific committees, attend plenary sessions, and participate in training sessions. These
conferences provide a forum for learning about clinical research science, planned or ongoing
trials, and clinical trial management. Community physicians acquire a greater understanding
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of the scientific relevance of particular questions and why certain protocol features may be
important for scientific rigor, while simultaneously providing input to the academic
researchers, who learn how to design trials that are clinically relevant, feasible in community
settings, and reflect the needs of the community itself. For example, minority physicians and
those serving minority men were persistent in communicating that African American men were
developing prostate cancer earlier than age 55, at the time a common age eligibility criterion
for many trials. By lowering the age eligibility criteria for African American men to 50, the
recruitment of these men was substantially enhanced 33. The end result of incorporating input
from community physicians is the ability to design scientifically rigorous trials that are feasible
to perform in the community, and also more likely to result in uptake into practice as
participating physicians have a venue in which to become familiar with the drugs and
procedures tested during the trial, observe their benefits for patients, and develop ways to
mitigate possible adverse effects.
Key Principle 4: Flexibility in operations of organizations
Individual CCOPs have flexibility regarding their structure and operating procedures, which
builds on the stability provided by predictable direct funding and the flexibility provided by
selecting which clinical trials to open from a large menu of options. This approach optimizes
the skills and interests of local clinicians as they work within the constraints of provider
organizations and patient populations. CCOP performance guidelines require that
organizations meet overall accrual targets, implement protection for human subjects, and
maintain standards for data quality set by their affiliated research bases; however, addressing
the reality that these provider organizations and populations vary widely in their characteristics,
priorities, and norms, CCOPs have wide latitude in how they do so. There are no requirements
regarding a specific organizational structure or size, number of open trials, or even accrual
targets for individual trials; rather, CCOPs largely self-design a system that works for them.
NCI program staff review each organization annually for overall performance and provide
technical assistance as needed, CCOP research bases periodically review each CCOP's data to
assure that it is meeting its quality standards, and each CCOP is peer reviewed every 3-5 years
when grants are openly competed.
This flexibility in strategies for meeting performance standards provides CCOP organizations
with considerable discretion in how they manage their operations. As demonstrated in the case
of the Upstate Carolina CCOP, CCOP organizations participate only in those trials that suit
the structure, function, needs, and interests of the affiliated providers and provider
organizations. Some CCOP organizations operate in a centralized manner from a single office,
while others utilize a more decentralized model with an administrative core that coordinates
research nurses individually employed by different participating physician practices. CCOP
organizations may also participate in non-health care settings, such as health information
booths at grocery store entrances or civic events, to distribute information and enroll
participants in cancer prevention trials. Many CCOP organizations employ outreach workers
to increase trial access for minority populations. These workers staff information booths at
minority-focused health events, make presentations in minority churches, and engage in
“academic detailing” in community-based organizations serving minority populations 27.
The CCOP program's flexibility is exemplified through the Minority Based CCOP (MBCCOP)
program, which evolved out of the recognition that, historically, most cancer care for minorities
has been at academic institutions. As such, academic centers were subsequently allowed to be
part of the MBCCOP program, in addition to the traditional community-based programs. These
sites serve as excellent venues for examining how well new agents, complex trial designs or
new technologies can be disseminated and implemented (or not) in special populations. These
sites typically have outreach services that inform the MBCCOP of referring physicians’ level
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of acceptance for a specific clinical/scientific advancement. Despite being comprised of only
13 local MBCCOP sites (compared to the other 47 CCOPs), the MBCCOP program allows the
inclusion of a substantial population of racial and ethnic minorities in studies, as demonstrated
in Figure 3, and facilitates their access to practice-based evidence and evidence-based practice.
Discussion
Historically, implementation and dissemination of new health care innovations have been slow.
For example, although it was known as early as 1601 that providing citrus to sailors would
prevent scurvy, not until 1795 did the British Navy order that citrus fruits be included as part
of the rations on all navy ships 52. More recently, a study of physician awareness and use of
the latest hypertension prevention, diagnosis, and treatment guidelines from NIH reported that
fewer than half of physicians followed guidelines for use of the latest prevention, diagnostic,
and treatment guidelines regarding hypertension, and 40% were not even aware of them 53.
This, despite data showing that more than half of the 50 million Americans with high blood
pressure are not being treated to goal even though their physicians understand that high blood
pressure is the most preventable cause of heart attack and stroke 54. There are similar examples
of lack of translation in almost all fields of medicine.
The CCOP network is an example of how PBRNs can be mechanisms to effectively address
the challenges facing clinical research and practice, continue medical progress that benefits
patients, providers, and society, and more effectively translate research into practice.
Organizational and funding flexibility together with meaningful, yet adaptable, performance
standards allow CCOPs to vary in terms of size, location, provider composition, and the types
of trials in which each site chooses to participate. These principles have enabled it to be a
vehicle for both including community oncologists as full partners in NCI's clinical trials
network and giving them a mechanism to both learn and use state-of-the-art treatments in the
context of national standards. In an environment of ever-changing local, state, and federal
regulatory burdens that often unintentionally constrict the health care and clinical research,
CCOPs’ firmly established internal processes enable the consistent and appropriate provision
of resources for sites to meet those requirements. These processes also allow for the
identification and engagement of competent and knowledgeable young investigators and
various support personnel for research careers within this PBRN framework.
Challenges will always face the development and sustainability of CCOPs and other PBRNs,
and for their continual adaptation. For example, recent advances in technology and clinical
research have resulted in the development of new drugs and methods of treatment that can be
increasingly complicated to use, let alone systematically implement as a part of a high quality
new standard of care in community practice. Accordingly, special attention needs to be given
to providing incentives to bring young clinician-investigators and research nurses into the
PBRN arena with their expertise in emerging technologies and practice skills. PBRNs can
provide a structured forum to observe and first utilize health care innovations, thus facilitating
their initial adoption and their subsequent systematic incorporation into practice.
Looking forward, even the CCOP network will find value in revisiting these principles in the
context of its continual evolution and adaptation to the changing landscape of cancer research.
Just as clinical cancer care is moving toward individualized therapies and personalized
medicine, so too is cancer clinical research. Clinical science is advancing to where antecedent
knowledge of individual biological variation is a factor driving not only outcomes, but also
treatment selection and even randomization within studies. CCOP practices will have to adapt
to these and other changes in order to continue to stay ahead of the curve in research. As the
CCOP Program seeks to continue to be on the vanguard of state-of-the-art translational science,
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and charts its future course following its recent program evaluation 55, it will benefit from
revisiting these guiding principles and grounding itself in them to help it successfully do so.
The CCOP structure has provided a framework for involving community patients and
practitioners in clinical research while simultaneously expediting the translation of clinical
research results into practice. With ever-growing emphasis on efficiency and, more recently,
new pressure to assess differential treatment effectiveness in the broader population, PBRNs
in other disease areas may find the CCOP experience useful for developing links between
community-based service delivery organizations and academic centers. This is critical for
meeting the challenge of translating research into practice.
Condensed Abstract
The National Institutes of Health and other programs are increasingly emphasizing research
involving evidence development, comparative effectiveness, translational research, and
accelerating the translation of research into evidence-based practice, as well as building
successful research networks to support these efforts. This manuscript describes the
National Cancer Institute's Community Clinical Oncology Program and its history of
successfully extending research into the community and facilitating the translation of
research into practice, and provides practical guidance to provider-based research networks
in cancer and other disciplines.
(Call out box.)
CCOP Principles for successfully addressing the major challenges facing PBRNs
• Develop and Maintain Infrastructure of Clinicians and Qualified Staff
• Maintain Adequate and Consistent Funding for Research
• Facilitate Collaborations Between Academic and Community Physicians
• Flexible Systems of Accountability and Efficiency
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Table 1
Overview, the NCI Community Clinical Oncology Program
The NCI Community Clinical Oncology Program
• Established in 1983
• Program Funds through Cooperative Agreements (peer reviewed grants)
    – Selected cancer centers and clinical cooperative groups (“CCOP research bases”) to design, develop and manage clinical trials; and
    – Community hospitals and physicians in local networks (“CCOP organizations”) to enroll patients onto cancer trials and disseminate study
findings in the community setting.
• Includes 47 CCOP organizations and 13 Minority-Based CCOP (MBCCOP) organizations located in 34 states, the District of Columbia, and
Puerto Rico in 2009 55.
• 60 CCOPs comprise 415 hospitals and nearly 3,440 community physicians in 2009 55.
Outcomes
• Currently contributes 1/3 of all enrollment to NCI trials, including 21% minorities 41, 55
• CCOP trials contribute to evidence-based national standards for cancer care
• CCOP-affiliated physicians participate in the development of clinical trials 25, 27.
• Disseminate national standards to community-based practices
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Table 2
Translating Bench to Bedside: Examples of Translation Facilitated by the Community Clinical Oncology
Program








Kras testing to guide introduction of chemotherapy 46 – CALGB C80405 – 574 (38%)*
– Only patients with a wild type
Kras benefit from EGFR
inhibitors, e.g., cetuximab
– Patients who will not benefit
from cetuximab can be identified
prior to treatment and avoid risks,
toxic side-effects, and substantial
costs of this chemo.
Personalized Medicine:
OncoType DX
OncoType DX Test to evaluate risk of breast cancer
recurrence56
– PACCT-1 (TAILORx) – 1,718 (25%)*
– Informing treatment choice:
Patients with low risk score are
unlikely to have recurrence and
may opt to forgo chemotherapy




Tamoxifen57-58 – NSABP-B-04 – Data not available
– NSABP-B-14
– Improvement in Overall
Survival for Early and Late Stage
Breast Cancer
– Reduction in Recurrence of




Trastuzumab (Herceptin) 59-62 – NSABP-B-31; – 850 (40%)
– NCCTG-N9831 – 743 (21%)
– Improvement in Survival
– Reduction in Recurrence of




Tamoxifen 30 – BCPT – 4,038 (30%)
Raloxifene 31 – STAR – 6,580 (33%)
– Reduction in the Risk of
Developing Breast Cancer
*
Approximated or estimated contribution based on data to-date; trials are ongoing or data are being finalized.
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